title: [Use of norethindrone .35 mg in disorders of the menstrual cycle].
authors.forename: A N
authors.initials: AN
authors.lastname: Ferrari
authors.forename: I
authors.initials: I
authors.lastname: Berge
authors.forename: C L
authors.initials: CL
authors.lastname: Rosito
authors.forename: M
authors.initials: M
authors.lastname: Russowsky
authors.forename: A B
authors.initials: AB
authors.lastname: Barbisan
authors.forename: T
authors.initials: T
authors.lastname: Roeche
mesh_terms: D003267:Contraception; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003276:Contraceptives, Oral; D004194:Disease; D004412:Dysmenorrhea; D005193:Family Planning Services; D008599:Menstruation Disturbances; D009640:Norethindrone; D011293:Premenstrual Syndrome; D012106:Research
chemical_list: D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003276:Contraceptives, Oral; D009640:Norethindrone
keywords: Clinical Research; Contraception; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Female--therapeutic use; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents, Progestin--therapeutic use; Contraceptive Agents--administraction and dosage; Contraceptive Agents--therapeutic use; Diseases; Dysmenorrhea; Family Planning; Menstruation Disorders; Norethindrone--administraction and dosage; Norethindrone--therapeutic use; Oral Contraceptives; Premenstrual Tension; Research Methodology